Literature DB >> 17723212

The expanding universe of regulatory T cell subsets in cancer.

Thomas F Gajewski1.   

Abstract

Evidence has indicated that failed antitumor immunity is dominated by immunosuppressive mechanisms within the tumor microenvironment. In this issue of Immunity, Peng et al. (2007) add to this list by describing tumor-infiltrating gammadelta T cells that have regulatory function.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17723212     DOI： 10.1016/j.immuni.2007.08.001

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  10 in total

1.  Specific recruitment of γδ regulatory T cells in human breast cancer.

Authors:  Jian Ye; Chunling Ma; Fang Wang; Eddy C Hsueh; Karoly Toth; Yi Huang; Wei Mo; Shuai Liu; Bing Han; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  Cancer Res       Date:  2013-08-19       Impact factor: 12.701

Review 2.  Adjuvant therapy for melanoma.

Authors:  Diwakar Davar; Ahmad A Tarhini; John M Kirkwood
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 3.  A user's perspective on GeoMxTM digital spatial profiling.

Authors:  Trieu My Van; Christian U Blank
Journal:  Immunooncol Technol       Date:  2019-05-30

4.  Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Authors:  Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Eric Wevers; Theresa Schwartz; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

Review 5.  Regulatory T cells and immune tolerance to tumors.

Authors:  Xuefang Cao
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

Review 6.  Human T regulatory cell therapy: take a billion or so and call me in the morning.

Authors:  James L Riley; Carl H June; Bruce R Blazar
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

7.  Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jian Yan; Xiao-Long Liu; Gang Xiao; Ning-Lei Li; Yi-Nan Deng; Lu-Zhe Han; Liang-Chun Yin; Li-Juan Ling; Li-Xin Liu
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

8.  The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

Authors:  Jason B Williams; Brendan L Horton; Yan Zheng; Yukan Duan; Jonathan D Powell; Thomas F Gajewski
Journal:  J Exp Med       Date:  2017-01-23       Impact factor: 14.307

9.  Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.

Authors:  Tan-Huan Chen; Ying-Chun Zhang; Yu-Ting Tan; Xin An; Cong Xue; Ying-Fei Deng; Wei Yang; Xia Yuan; Yan-Xia Shi
Journal:  Oncotarget       Date:  2017-01-17

10.  CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B.

Authors:  Yuejiao Dong; Xuefen Li; Lu Zhang; Qiaoyun Zhu; Chunlei Chen; Jiaqi Bao; Yu Chen
Journal:  BMC Immunol       Date:  2019-08-07       Impact factor: 3.615
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.